May Measurement Month 2018: an analysis of blood pressure screening results from Colombia.

Blood pressure Control Hypertension Screening Treatment

Journal

European heart journal supplements : journal of the European Society of Cardiology
ISSN: 1520-765X
Titre abrégé: Eur Heart J Suppl
Pays: England
ID NLM: 100886647

Informations de publication

Date de publication:
Aug 2020
Historique:
entrez: 5 9 2020
pubmed: 5 9 2020
medline: 5 9 2020
Statut: ppublish

Résumé

High blood pressure (BP) is the leading global preventable cause of death and the most common risk factor for cardiovascular disease (CVD). However, due to its asymptomatic nature, the lack of awareness of this condition causes underdiagnosis and low rates of adherence to pharmacological treatment. Looking for practical approaches to increase awareness worldwide, the International Society of Hypertension (ISH) implemented the 2nd May Measurement Month campaign in 2018 (MMM18). In order to contribute to this initiative, Colombia participated as one of the 89 countries involved in this hypertension screening programme. Blood pressure was measured in subjects from 11 departments in Colombia. Under the leadership of the Fundación Oftalmológica de Santander (FOSCAL), 400 volunteers across the country collected the data following the MMM protocol. Measurements from 35 548 participants with a mean age of 41.9 years were obtained. In total, 9475 (26.7%) of the total population studied had hypertension. Of those with hypertension, 69.9% of these subjects were aware of their condition, 65.0% were on antihypertensive medication, and 43.1% had controlled BP. Of those on medication, 66.3% had controlled BP. Hypertension screening, awareness, treatment, and control should be a priority in public health objectives due to its elevated burden of disease and direct association with increased CVD. The MMM campaign provided a positive impact in the diagnosis of hypertension across Colombia. Although efforts are being made to expand treatment capability and adherence, still more are needed to insure a broader coverage of antihypertensive medication in Colombia.

Identifiants

pubmed: 32884467
doi: 10.1093/eurheartj/suaa025
pii: suaa025
pmc: PMC7455303
doi:

Types de publication

Journal Article

Langues

eng

Pagination

H43-H46

Informations de copyright

Published on behalf of the European Society of Cardiology. © The Author(s) 2020.

Références

Eur Heart J Suppl. 2019 Apr;21(Suppl D):D40-D43
pubmed: 31043874
Lancet. 2016 Nov 26;388(10060):2665-2712
pubmed: 27671667
Lancet. 2020 Mar 7;395(10226):795-808
pubmed: 31492503
J Hypertens. 2019 Jun;37(6):1126-1147
pubmed: 30882601
Eur Heart J. 2019 Jul 1;40(25):2092
pubmed: 31005984
Lancet. 2019 Oct 5;394(10205):1231-1242
pubmed: 31488369
Eur Heart J. 2019 Jul 1;40(25):2006-2017
pubmed: 31041440
Lancet. 2020 Mar 7;395(10226):785-794
pubmed: 31492501
J Am Coll Cardiol. 2015 Apr 7;65(13):1371-1372
pubmed: 25835450

Auteurs

Patricio Lopez-Jaramillo (P)

Instituto de Investigaciones Masira, Facultad de Ciencias de la Salud, Universidad de Santander (UDES), Lagos del Cacique, Bucaramanga, Santander, Colombia.
Dirección de Investigaciones, Fundación Oftalmológica de Santander (FOSCAL), Calle 155 A 23 04, El Bosque, Floridablanca, Santander, Colombia.

Johanna Otero (J)

Instituto de Investigaciones Masira, Facultad de Ciencias de la Salud, Universidad de Santander (UDES), Lagos del Cacique, Bucaramanga, Santander, Colombia.
Dirección de Investigaciones, Fundación Oftalmológica de Santander (FOSCAL), Calle 155 A 23 04, El Bosque, Floridablanca, Santander, Colombia.

Juliana Alvernia (J)

Dirección de Investigaciones, Fundación Oftalmológica de Santander (FOSCAL), Calle 155 A 23 04, El Bosque, Floridablanca, Santander, Colombia.

Daniela Ney-Salazar (D)

Dirección de Investigaciones, Fundación Oftalmológica de Santander (FOSCAL), Calle 155 A 23 04, El Bosque, Floridablanca, Santander, Colombia.

Jose Lopez-Lopez (J)

Dirección de Investigaciones, Fundación Oftalmológica de Santander (FOSCAL), Calle 155 A 23 04, El Bosque, Floridablanca, Santander, Colombia.

Jose L Accini (JL)

IPS Centro Científico Asistencial, Carrera 43b #80-101, Barranquilla, Atlántico, Colombia.
Unidad de cuidados críticos, Facultad de Medicina Universidad Libre and Universidad del Norte, Km. 7 Antigua Vía Puerto Colombia, Barranquilla, Atlántico, Colombia.

Gustavo Aroca (G)

Facultad de Medicina, Universidad Simón Bolívar and Clínica de la Costa, Carrera 50 80-90, Barranquilla, Atlántico, Colombia.

Miguel Urina-Triana (M)

Facultad de Medicina, Universidad Simón Bolívar and Clínica de la Costa, Carrera 50 80-90, Barranquilla, Atlántico, Colombia.

Gregorio Sánchez-Vallejo (G)

Fundacion Centro de Obesidad y Metabolismo COMETA, Carrera 36 # 19-94 Barrio Palermo, Pasto, Colombia.

Edgar Arcos (E)

Programa de Medicina Interna, Universidad Libre, Carrera 37A #3-29 Cali, Colombia.

María E Casanova (ME)

Departamento de Investigación Clínica, Fundación Centro de Investigaciones Biomédicas (RIESCARD), Carrera 5 #1870, El Espinal, Tolima, Colombia.

Henry García (H)

Departamento de Investigación Clínica, Fundación Centro de Investigaciones Biomédicas (RIESCARD), Carrera 5 #1870, El Espinal, Tolima, Colombia.

Thomas Beaney (T)

Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
Department of Primary Care and Public Health, Imperial College London, St Dunstan's Road, London W6 8RP, UK.

Anca Chis Ster (AC)

Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.

Neil R Poulter (NR)

Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.

Classifications MeSH